# A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

> **NCT01328093** · PHASE3 · TERMINATED · sponsor: **Denovo Biopharma LLC** · enrollment: 678 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LY2140023
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01328093
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 678 (ACTUAL)
- **Why stopped:** The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328093, "A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01328093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*